AstraZeneca (LSE: AZN) has launched FluMist Home, the first FDA-approved influenza vaccine program that allows self- or ...

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

Japan’s Mochida Pharmaceutical has announced that Lialda (mesalazine 600mg) the will be launched on September 8, 2025, as the NHI (National Health Insurance) Drug Price was listed on August 14, 2025.

Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug ...

Shares of New Jersey, USA-based Tonix Pharmaceuticals rose 15.5% to $59.31 in after-hours trading on Friday, after the ...

Costco (Nasdaq: COST) has confirmed it will not sell the abortion pill mifepristone, which is sold under the Mifeprex brand, ...

Flagship Pioneering has appointed Ajit Singh as chief executive (CEO)-partner of Flagship and the new CEO of Harbinger Health ...

The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by ...

Schrödinger (Nasdaq: SDGR) has halted the clinical development of its oral drug SGR-2921 following the occurrence of two ...

The Swiss government has met with senior executives from Roche (ROG: SIX) and Novartis (NOVN: VX) to discuss the outlook for ...

Swiss drug developer Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals, to ...